Oxidation of Protein Kinase A Regulatory Subunit PKARIα Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
02 02 2021
Historique:
pubmed: 14 11 2020
medline: 30 12 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

Kinase oxidation is a critical signaling mechanism through which changes in the intracellular redox state alter cardiac function. In the myocardium, PKARIα (type-1 protein kinase A) can be reversibly oxidized, forming interprotein disulfide bonds in the holoenzyme complex. However, the effect of PKARIα disulfide formation on downstream signaling in the heart, particularly under states of oxidative stress such as ischemia and reperfusion (I/R), remains unexplored. Atrial tissue obtained from patients before and after cardiopulmonary bypass and reperfusion and left ventricular (LV) tissue from mice subjected to I/R or sham surgery were used to assess PKARIα disulfide formation by immunoblot. To determine the effect of disulfide formation on PKARIα catalytic activity and subcellular localization, live-cell fluorescence imaging and stimulated emission depletion super-resolution microscopy were performed in In both humans and mice, myocardial PKARIα disulfide formation was found to be significantly increased (2-fold in humans, Disulfide modification targets PKARIα to the lysosome, where it acts as a gatekeeper for two-pore channel-mediated triggering of global calcium release. In the postischemic heart, this regulatory mechanism is critical for protection from extensive injury and offers a novel target for the design of cardioprotective therapeutics.

Sections du résumé

BACKGROUND
Kinase oxidation is a critical signaling mechanism through which changes in the intracellular redox state alter cardiac function. In the myocardium, PKARIα (type-1 protein kinase A) can be reversibly oxidized, forming interprotein disulfide bonds in the holoenzyme complex. However, the effect of PKARIα disulfide formation on downstream signaling in the heart, particularly under states of oxidative stress such as ischemia and reperfusion (I/R), remains unexplored.
METHODS
Atrial tissue obtained from patients before and after cardiopulmonary bypass and reperfusion and left ventricular (LV) tissue from mice subjected to I/R or sham surgery were used to assess PKARIα disulfide formation by immunoblot. To determine the effect of disulfide formation on PKARIα catalytic activity and subcellular localization, live-cell fluorescence imaging and stimulated emission depletion super-resolution microscopy were performed in
RESULTS
In both humans and mice, myocardial PKARIα disulfide formation was found to be significantly increased (2-fold in humans,
CONCLUSIONS
Disulfide modification targets PKARIα to the lysosome, where it acts as a gatekeeper for two-pore channel-mediated triggering of global calcium release. In the postischemic heart, this regulatory mechanism is critical for protection from extensive injury and offers a novel target for the design of cardioprotective therapeutics.

Identifiants

pubmed: 33185461
doi: 10.1161/CIRCULATIONAHA.120.046761
pmc: PMC7846288
doi:

Substances chimiques

Cyclic AMP-Dependent Protein Kinase RIalpha Subunit 0
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

449-465

Subventions

Organisme : Medical Research Council
ID : MR/S005382/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : AA/18/2/34218
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/12/3/29423
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/1/32013
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/10/32859
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/19/33/34385
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700320
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/12/3/29609
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/07/003/23133
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/11/15/29375
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/10/75/28537
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/12/5/29576
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R01065X/2
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/44/33064
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01577X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P023150/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/6/32944
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 0998981Z/12/Z
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/66/32288
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/12/32451
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/9/31534
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/17/32438
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R01065X/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/5/31110
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P023150/2
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/16/33294
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Références

J Biol Chem. 2006 Jul 28;281(30):21535-45
pubmed: 16728392
Cancer Res. 2005 Nov 15;65(22):10307-15
pubmed: 16288019
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19266-19275
pubmed: 32703809
Structure. 2010 Feb 10;18(2):155-66
pubmed: 20159461
J Mol Med (Berl). 2012 Dec;90(12):1391-406
pubmed: 23090009
Cardiovasc Res. 2015 Dec 1;108(3):357-66
pubmed: 26395965
Mol Pharmacol. 1979 Mar;15(2):235-45
pubmed: 89626
Circ Res. 2001 Apr 27;88(8):802-9
pubmed: 11325872
Sci Rep. 2017 Jan 17;7:40620
pubmed: 28094777
Free Radic Biol Med. 2018 Mar;117:76-89
pubmed: 29373843
Circ Res. 2008 Oct 10;103(8):836-44
pubmed: 18757829
Cardiovasc Res. 2017 Dec 1;113(14):1743-1752
pubmed: 29016722
FASEB J. 2005 Dec;19(14):2037-9
pubmed: 16236999
Circulation. 1994 May;89(5):1982-91
pubmed: 8181121
Am J Physiol. 1996 May;270(5 Pt 2):H1772-8
pubmed: 8928885
Circ Res. 2007 Feb 16;100(3):391-8
pubmed: 17234966
Biochem Pharmacol. 2015 Feb 1;93(3):362-9
pubmed: 25437456
J Biol Chem. 2004 Oct 1;279(40):41352-60
pubmed: 15292244
Trends Cardiovasc Med. 2014 Jul;24(5):202-5
pubmed: 24880746
Cardiovasc Res. 2006 May 1;70(2):181-90
pubmed: 16580655
Cardiovasc Res. 2014 Apr 1;102(1):79-87
pubmed: 24501329
J Biol Chem. 2007 May 18;282(20):15302-11
pubmed: 17387177
Opt Lett. 1994 Jun 1;19(11):780-2
pubmed: 19844443
Annu Rev Physiol. 2008;70:23-49
pubmed: 17988210
Cardiovasc Res. 2018 May 1;114(6):858-869
pubmed: 29509881
J Mol Cell Cardiol. 2014 Oct;75:206-15
pubmed: 25073061
PLoS One. 2013 Oct 10;8(10):e77129
pubmed: 24130844
Front Biosci. 2000 Aug 01;5:D678-93
pubmed: 10922298
Cardiovasc Res. 2012 May 1;94(2):168-80
pubmed: 22499772
Circ Res. 2001 Aug 31;89(5):445-52
pubmed: 11532906
J Biol Chem. 2009 Oct 23;284(43):29260-8
pubmed: 19726669
Sci Rep. 2017 Oct 26;7(1):14090
pubmed: 29074866
Circ Res. 1997 May;80(5):743-8
pubmed: 9130455
J Biol Chem. 2005 Apr 8;280(14):13279-84
pubmed: 15691833
Sci Rep. 2016 Feb 03;6:20282
pubmed: 26838264
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113
pubmed: 29221659
Arch Med Res. 2018 Nov;49(8):530-537
pubmed: 30642654
Eur Heart J. 2013 Jun;34(23):1714-22
pubmed: 23536610
Mol Cell. 2006 Nov 3;24(3):383-95
pubmed: 17081989
Circulation. 2004 Mar 2;109(8):962-5
pubmed: 14981009
Circ Res. 1995 Aug;77(2):424-9
pubmed: 7614726
Chem Rev. 2013 Jul 10;113(7):4633-79
pubmed: 23514336
Circ Res. 2002 Dec 13;91(12):1168-75
pubmed: 12480818
Cardiovasc Res. 2001 Oct;52(1):95-102
pubmed: 11557237
Biophys J. 2018 Oct 2;115(7):1146-1155
pubmed: 30219286
Nat Commun. 2015 Aug 10;6:7920
pubmed: 26258640
Medicine (Baltimore). 2017 Apr;96(15):e6591
pubmed: 28403095
J Biol Chem. 2006 Aug 4;281(31):21827-36
pubmed: 16754666
Antioxid Redox Signal. 2013 Mar 20;18(9):1042-52
pubmed: 22867279
J Biol Chem. 2015 Dec 11;290(50):30087-98
pubmed: 26438825
J Microsc. 2006 Dec;224(Pt 3):213-32
pubmed: 17210054
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1454-65
pubmed: 20207816
Diabetes. 2005 Jan;54(1):146-51
pubmed: 15616022
Circ Res. 2012 Aug 31;111(6):718-27
pubmed: 22798524
Eur Heart J. 2012 Jun;33(12):1491-9
pubmed: 21920963
Circ Res. 2013 Apr 12;112(8):1135-49
pubmed: 23476056

Auteurs

Jillian N Simon (JN)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Besarte Vrellaku (B)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Stefania Monterisi (S)

Department of Physiology, Anatomy and Genetics (S.M., P.S., M.Z.), University of Oxford, United Kingdom.

Sandy M Chu (SM)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Nadiia Rawlings (N)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Oliver Lomas (O)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Gerard A Marchal (GA)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Dominic Waithe (D)

Wolfson Imaging Centre, Weatherall Institute of Molecular Medicine (D.W.), University of Oxford, United Kingdom.

Fahima Syeda (F)

Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (F.S., L.F.).

Parag R Gajendragadkar (PR)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Raja Jayaram (R)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Rana Sayeed (R)

Cardiothoracic Surgery, Oxford Heart Centre, Oxford University Hospitals National Health Service Foundation Trust, United Kingdom (R.S.).

Keith M Channon (KM)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Larissa Fabritz (L)

Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom (F.S., L.F.).
Department of Cardiology, University Hospitals Birmingham, United Kingdom (L.F.).

Pawel Swietach (P)

Department of Physiology, Anatomy and Genetics (S.M., P.S., M.Z.), University of Oxford, United Kingdom.

Manuela Zaccolo (M)

Department of Physiology, Anatomy and Genetics (S.M., P.S., M.Z.), University of Oxford, United Kingdom.

Philip Eaton (P)

William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, United Kingdom (P.E.).

Barbara Casadei (B)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine (J.N.S., B.V., S.M.C., N.R., O.L., G.A.M., P.R.G., R.J., K.M.C., B.C.), University of Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH